Key result
Aliskiren reduced portal pressure and intrahepatic vasoconstriction in bile duct ligated cirrhotic rats.
Why the study?
Does aliskiren reduce portal pressure and intrahepatic resistance in bile duct ligated cirrhotic rats?
Does aliskiren reduce portal pressure and intrahepatic resistance in bile duct ligated cirrhotic rats?
Answers are grounded in this paper and cite their sources.
Aliskiren reduces portal pressure and intrahepatic resistance in a rat model of biliary cirrhosis by ameliorating Ang II-induced vasoconstriction.
BACKGROUND: It is a well-accepted fact that angiotensin II (Ang II) contributes to increased vascular tone in cirrhotic livers. However, aliskiren attenuates the effect of Ang II through direct renin inhibition. Our study aimed to evaluate the effects of aliskiren on portal pressure and intrahepatic resistance in bile duct ligated (BDL) rats. METHODS: The effects of acute intravenous infusion (1 mg or 3 mg) or a course of 2-day oral administration of aliskiren (20 mg/kg/day) on blood pressure and portal pressure were evaluated in BDL and sham rats. Intrahepatic resistance was evaluated by a liver perfusion study isolated in situ. Ang II efflux was measured by Enzyme-linked immunosorbent assay (ELISA). The hepatic gene expression of angiotensinogen, renin, angiotensin-converting enzyme (ACE), Ang II type 1 receptor (AT(1)R) was analyzed with quantitative reverse transcription polymerase chain reaction. RESULTS: Aliskiren infusion intravenously reduced portal pressure with a minimal effect on blood pressure in BDL rats. Direct infusion of aliskiren in an isolated cirrhotic liver caused greater vasorelaxation and decreased hepatic production of Ang II. Two days of aliskiren treatment reduced portal pressure and hepatic ACE mRNA; in addition, it improved the vasodilator response to acetylcholine in the cirrhotic livers and decreased Ang II efflux. CONCLUSION: Aliskiren reduced portal pressure in cirrhotic rats. The portal hypotensive effect of aliskiren was related to the amelioration of the Ang II induced intrahepatic vasoconstriction.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2012) studied Biliary cirrhosis. Aliskiren vs. Sham rats was evaluated on Portal pressure and intrahepatic resistance. Aliskiren reduced portal pressure and intrahepatic vasoconstriction in bile duct ligated cirrhotic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: